ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Friday, May 15, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss first quarter 2026 financial results and business highlights.

Rhea-AI Summary

ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Friday, May 15, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss first quarter 2026 financial results and business highlights. Dial-in details require event registration. A webcast replay will be available for 30 days.

Argus May 7 session

-3.02% close to close Open Argus

Details

News Market Reaction – SPRY

In the May 7 session, SPRY declined 3.02%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for ARS Pharmaceuticals’ first quarter 2026 financial results d...

Analysis

This announcement sets the timetable for ARS Pharmaceuticals’ first quarter 2026 financial results discussion, continuing a consistent pattern of quarterly conference-call notices. Historically, similar “conferences,earnings” updates produced modest average moves of about 0.31%, suggesting these releases function mainly as logistical milestones. Investors may focus on the upcoming call for detailed revenue trends, expense trajectories, and updates on neffy’s commercialization and pipeline progress.

Key Figures

Conference date: May 15, 2026 Conference time PT: 5:30 a.m. PT Conference time ET: 8:30 a.m. ET +5 more

Conference date

May 15, 2026

First quarter 2026 earnings call

Conference time PT

5:30 a.m. PT

Start time for Q1 2026 call

Conference time ET

8:30 a.m. ET

Start time for Q1 2026 call

Webcast replay window

30 days

Replay availability after event

Current price

$9.295

Before Q1 2026 call announcement reaction

Price vs 52-week high

-50.82%

Distance from 52-week high of $18.9

24h price change

2.77%

Move ahead of Q1 2026 conference call

Volume relative

1.66x

Compared with 20-day average volume

Previous Conferences,earnings Reports

5 past events · Latest: Feb 23

Same Type 5 events

1. Feb 23

   Earnings call notice

   24h Move

   +2.3%

   Announced timing for Q4 and full-year 2025 results and conferences.

2. Nov 03

   Earnings call notice

   24h Move

   -3.8%

   Set date and time for Q3 2025 financial results discussion.

3. Aug 04

   Earnings call notice

   24h Move

   +1.2%

   Scheduled Q2 2025 financial results conference call and webcast.

4. May 05

   Earnings call notice

   24h Move

   -1.4%

   Announced Q1 2025 results call and webcast logistics for investors.

5. Mar 03

   Earnings call notice

   24h Move

   +3.2%

   Outlined Q4 2024 results call and participation at investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

anaphylaxis

1 terms

anaphylaxis medical

"better protect patients from allergic reactions that could lead to anaphylaxis, today announced"

Anaphylaxis is a sudden, severe allergic reaction in which the body's defense system overreacts to a trigger (like a drug, food, or insect sting), causing widespread symptoms such as difficulty breathing, low blood pressure, and shock; it can be life‑threatening without prompt treatment. Investors care because anaphylaxis risks can affect a drug or product's safety profile, regulatory approval, liability exposure and market acceptance—similar to a sprinkler system going off and damaging the whole house rather than just one room.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights.

Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy^® (trade name EURneffy^® in the EU and 优敏速^® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

Investor Contact:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com

Monique Allaire
THRUST
monique@thrustsc.com

Media Contact:
Christy Curran
Sam Brown Inc.
615.414.8668
christycurran@sambrown.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ARS Pharmaceuticals (SPRY) report Q1 2026 results and hold the conference call?

The conference call is scheduled for May 15, 2026 at 5:30 a.m. PT / 8:30 a.m. ET. According to the company, the call will cover first quarter 2026 financial results and business highlights, followed by a webcast with slides.

How can investors access the ARS Pharmaceuticals (SPRY) webcast for the May 15, 2026 call?

Investors can access the live webcast and slides via the Events & Presentations page on the company website. According to the company, registration details and the webcast link will be posted in the Investors & Media section.

Is registration required to obtain dial-in information for the ARS Pharmaceuticals (SPRY) conference call?

Yes, dial-in information is available by registering for the event. According to the company, conference participants must register to receive dial-in details and join the live call.

Will a replay of the ARS Pharmaceuticals (SPRY) May 15, 2026 webcast be available after the event?

A replay will be available for 30 days following the event. According to the company, the webcast replay and slides will remain accessible on the Events & Presentations page for that 30-day period.

What topics will ARS Pharmaceuticals (SPRY) cover during the Q1 2026 conference call?

The company will discuss first quarter 2026 financial results and business highlights. According to the company, the conversation will include results commentary and summary updates relevant to investors and stakeholders.